Last reviewed · How we verify
CLOBETASOL
At a glance
| Generic name | CLOBETASOL |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
- Burning and/or stinging sensation
- Scalp pustules
- Tingling
- Folliculitis
- Itching
- Tightness of the scalp
- Dermatitis
- Tenderness
- Headache
- Hair loss
- Eye irritation
- Burning
Serious adverse events
- HPA axis suppression
- Cushing's syndrome manifestations
- Hyperglycemia
- Glucosuria
- Secondary infection
- Skin atrophy
- Striae
- Miliaria
- Exacerbation of psoriasis
- Pustular psoriasis
Key clinical trials
- Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody (PHASE2)
- Clinical Trial to Demonstrate That the Dual Laser Therapy is Effective for the Treatment of Vulvar Lichen Sclerosus (NA)
- Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (PHASE2)
- Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) (PHASE1)
- Effectiveness of Micro-needling With 5 Fluorouracil Versus Potent Topical Steroids in the Treatment of Limited Vitiligo (EARLY_PHASE1)
- Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid (PHASE4)
- Fractionated 1927nm Laser for Hyperpigmentation in Fitzpatrick Skin Phototypes V and VI (NA)
- Photobiomodulation, Er:YAG Laser, and Clobetasol in the Treatment of Oral Lichen Planus. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |